|
Age (<50 vs. ≥50)
|
1.21 (0.59-2.51)
|
0.61
| | |
1.24 (0.69-2.21)
|
0.47
| | |
|
ECOG PS (0 vs. 1 or 2)
|
0.45 (0.22-0.95)
|
0.04
|
0.53 (0.25-1.12)
|
0.1
|
0.48 (0.27-0.87)
|
0.02
|
0.57 (0.31-1.03)
|
0.06
|
|
Tumor shape (exophytic vs. infiltrative)
|
1.75 (0.85-3.64)
|
0.13
| | |
1.75 (0.98-3.14)
|
0.06
|
1.67 (0.93-2.99)
|
0.09
|
|
Tumor size (<5 vs. ≥5 cm)
|
0.67 (0.3-1.47)
|
0.31
| | |
0.72 (0.39-1.33)
|
0.29
| | |
|
Parametrial involvement (no vs. yes)
|
0.4 (0.1-1.7)
|
0.22
| | |
0.5 (0.18-1.39)
|
0.18
| | |
|
Endocervical extension (others vs. yes)
|
1.85 (0.82-4.17)
|
0.14
| | |
1.47 (0.8-2.7)
|
0.22
| | |
|
Pelvic nodal involvement (no vs. yes)
|
0.78 (0.32-1.91)
|
0.58
| | |
0.71 (0.34-1.47)
|
0.35
| | |
|
Hydronephrosis (no vs. yes)
|
1.21 (0.42-3.5)
|
0.72
| | |
0.82 (0.4-1.65)
|
0.57
| | |
|
Stage (IB vs. IIB vs. IIIA-IVA)
|
Referent 0.38 (0.09-1.7)
|
0.45
| | |
Referent 0.45 (0.15-1.3)
|
0.32
| | |
|
0.9 (0.42-1.92)
| | | |
0.81 (0.44-1.49)
| | | |
|
Radiotherapy duration (<10 vs. ≥10 weeks)
|
0.59 (0.28-1.23)
|
0.16
| | |
0.62 (0.35-1.12)
|
0.11
| | |
|
Doses to point A (<75 vs. ≥75 Gy)
|
0.87 (0.42-1.8)
|
0.71
| | |
0.64 (0.36-1.15)
|
0.14
| | |
|
Doses to PAN (<50.4 vs. ≥50.4 Gy)
|
1.09 (0.46-2.55)
|
0.85
| | |
0.75 (0.35-1.6)
|
0.45
| | |
|
Treatment period (<2000 vs. ≥2000)
|
1.25 (0.59-2.65)
|
0.56
| | |
0.98 (0.54-1.76)
|
0.95
| | |
|
Treatment response (CR vs. PR)
|
0.36 (0.16-0.81)
|
0.01
|
0.43 (0.19-0.98)
|
0.04
|
0.27 (0.14-0.51)
|
<0.001
|
0.3 (0.16-0.58)
|
<0.001
|
|
Concurrent chemotherapy (no vs. yes)
|
1.23 (0.59-2.54)
|
0.59
| | |
0.88 (0.49-1.57)
|
0.65
| | |
